• CONMED annual report for fiscal 2025 outlined continued execution on strategy focused on minimally invasive surgery, smoke evacuation, orthopedic soft-tissue repair.
• Portfolio review drove decision to exit gastroenterology product line, shifting resources toward higher-growth platforms.
• Supply chain work reduced orthopedic sports medicine backorders to a three-year low, with further improvement cited in early 2026.
• Capital allocation shifted with dividend suspension effective Oct. 31, 2025, paired with authorization of a USD 150 million share repurchase program.
• Leadership changes included CFO Todd Garner set to step down effective March 15, 2026, with an executive search underway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CONMED Corporation published the original content used to generate this news brief on April 07, 2026, and is solely responsible for the information contained therein.